Michael Burgess Net Worth

Michael Burgess biography

Dr. Michael F. Burgess Ph.D. serves as Independent Director of the Company. Prior to joining Turnstone, Dr. Burgess led strategy and execution of translational medicine, early-stage clinical trials and clinical pharmacology across all therapeutic areas, including oncology at Bristol-Myers Squibb from January 2013 to September 2017. Prior to this, he held several senior leadership positions at Roche Pharmaceuticals, including acting global head of Roche Pharma Research and Early Development (pRED) and Senior Vice President and Global Head of Oncology Research and Early Development. Before joining Roche, Dr. Burgess spent seven years at Eli Lilly and Company working on early stage oncology trials. Dr. Burgess received his medical degree (M.B., Ch.B.) and a Ph.D. in molecular biology from the University of Bristol, UK and spent 10 years as a practicing physician in pediatrics and pediatric oncology. The Board has concluded that Dr. Burgess possesses specific attributes that qualify him to serve as a member of our Board, including his experience in senior management positions in drug research and development at a number of leading pharmaceutical companies. 10

How old is Michael Burgess?

Michael Burgess is 57, he's been the Independent Director of Synlogic Inc since 2020. There are 3 older and 12 younger executives at Synlogic Inc. The oldest executive at Synlogic Inc is Richard Shea, 68, who is the Independent Director.

What's Michael Burgess's mailing address?

Michael's mailing address filed with the SEC is C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE, MA, 02142.

Insiders trading at Synlogic Inc

Over the last 7 years, insiders at Synlogic Inc have traded over $330,991 worth of Synlogic Inc stock and bought 17,000 units worth $31,190 . The most active insiders traders include Forest Baskett, Scott D Sandell и Anthony A. Jr. Florence. On average, Synlogic Inc executives and independent directors trade stock every 132 days with the average trade being worth of $7,257. The most recent stock trade was executed by Mary Beth Dooley on 2 April 2024, trading 188 units of SYBX stock currently worth $325.

What does Synlogic Inc do?

at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre

Synlogic Inc executives and stock owners

Synlogic Inc executives and other stock owners filed with the SEC include:

• Aoife Brennan,
  President, Chief Executive Officer, Director
• Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc,
  Pres, CEO & Director
• Antoine Awad,
  Chief Operating Officer
• Richard Riese,
  Chief Medical Officer
• Patricia Hurter,
  Independent Director
• Peter Barrett,
  Independent Chairman of the Board
• Richard Shea,
  Independent Director
• Edward Mathers,
  Independent Director
• Nick Leschly,
  Independent Director
• Chau Khuong,
  Independent Director
• Michael Burgess,
  Independent Director
• Michael Slater,
  Head of Regulatory Affairs
• David Hava,
  Chief Scientific Officer
• Gregg Beloff,
  Interim Chief Financial Officer
• Ajay Munshi,
  VP of Corp. Devel.
• Adam Thomas,
  Chief People Officer & Sec.
• Michael Jensen,
  Chief Financial Officer
• Dr. Timothy K. Lu M.D., Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Michael Conlon,
  VP of Corp. Devel.
• Brendan St. Amant,
  Head of Legal
• Daniel Rosan,
  Sr. VP & Head of Investor Relations
• Dr. Elizabeth Wolffe,
  Head of Investor Relations & Corp. Communications
• Dr. David L. Hava Ph.D.,
  Chief Scientific Officer
• Gregg D. Beloff J.D., M.B.A.,
  Interim Chief Financial Officer
• Dr. James J. Collins Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Dr. Timothy K. Lu,
  Co-Founder
• Todd Shegog,
  See Remarks
• Scott D Sandell,
  10% owner
• Ravi Viswanathan,
  10% owner
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Forest Baskett,
  10% owner
• Michael Powell,
  Director
• Peter W. Sonsini,
  10% owner
• Patrick J Kerins,
  10% owner
• M James Barrett,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 14, L...,
  
• Advisors Llc Orbi Med Capit...,
  
• Jose Carlos Gutierrez Ramos,
  See Remarks
• Paul Francis Miller,
  Chief Scientific Officer
• Scott Eric Plevy,
  Chief Scientific Officer
• Michael Vangsted Jensen,
  Chief Financial Officer
• Antoine Awad,
  Chief Operating Officer
• Michael Thomas Heffernan,
  
• Lisa Kelly Croswell,
  
• James P Flynn,
  
• Mary Beth Dooley,
  Head of Finance